Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
19.31
-0.62 (-3.11%)
At close: May 13, 2025, 4:00 PM
19.52
+0.21 (1.09%)
Pre-market: May 14, 2025, 4:52 AM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Total Royalties | 17.35B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Royalties Growth | 26.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reimbursement | 996.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reimbursement Growth | 15.28% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Milestone | 1.00B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Milestone Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| License | 2.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| DARZALEX Royalties | 13.92B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| DARZALEX Royalties Growth | 23.59% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kesimpta Royalties | 2.22B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kesimpta Royalties Growth | 48.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TEPEZZA Royalties | 737.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TEPEZZA Royalties Growth | 4.69% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Royalties | 471.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Royalties Growth | 94.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Collaboration | 433.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Collaboration Growth | 41.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Net Product Sales | 1.74B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Janssen | 14.42B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Janssen Growth | 20.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Novartis | 2.82B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Novartis Growth | 86.76% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioNTech | 869.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioNTech Growth | 10.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pfizer | 533.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pfizer Growth | 42.90% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Collaboration Partner | 2.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Collaboration Partner Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Roche | 741.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Roche Growth | 5.26% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AbbVie | 394.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AbbVie Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Denmark | 19.78B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Denmark Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States | 902.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan | 841.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|